CASI CMO reports 116,333 vested stock options

CASI Pharmaceuticals, Inc. executive Alexander A. Zukiwski, Global Chief Medical Officer, reported his derivative holdings on a Form 3.

Accepted by SEC EDGAR 04/03/2026 - 04:30 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

CASI Pharmaceuticals, Inc. executive Alexander A. Zukiwski, Global Chief Medical Officer, reported his derivative holdings on a Form 3. He holds fully vested stock options giving him the right to buy a total of 116,333 Ordinary Shares at an exercise price of $1.93 per share, with each option grant expiring on April 20, 2027. The footnote states that all of these options are fully vested and exercisable as of the date of the form, meaning he can choose to convert any or all of them into shares at the stated price.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Zukiwski Alexander A

Role Global Chief Medical Officer

Type	Security	Shares	Price	Value
Holding	Option (right to buy)	--	--	--
Holding	Option (right to buy)	--	--	--
Holding	Option (right to buy)	--	--	--
Holding	Option (right to buy)	--	--	--
Holding	Option (right to buy)	--	--	--

Holdings: Option (right to buy) — 116,333 contracts (Direct)

Footnotes (1)

1. F1. The options are fully vested and exercisable as of the date of this form.

Key Figures

Total underlying shares: 116,333 shares Exercise price: $1.93 per share Option block 1: 30,000 shares +2 more

5 metrics

Total underlying shares 116,333 shares Underlying Ordinary Shares covered by all reported options

Exercise price $1.93 per share Exercise price for each reported option grant

Option block 1 30,000 shares Underlying Ordinary Shares for one option position, direct ownership

Option block 2 50,000 shares Largest single option position reported, direct ownership

Option expiration date April 20, 2027 Expiration date for all reported options

Key Terms

Option (right to buy), Ordinary Share, fully vested and exercisable, Form 3

4 terms

Option (right to buy) financial

"security_title": "Option (right to buy)""

Ordinary Share financial

"underlying_security_title": "Ordinary Share""

An ordinary share is a unit of ownership in a company that gives the holder a stake in its profits and usually the right to vote on key decisions. Think of it like a slice of a pizza where each slice entitles you to a portion of what’s left after bills are paid; value can rise or fall with the business and may pay dividends, so it matters to investors for income, growth and control.

fully vested and exercisable financial

"The options are fully vested and exercisable as of the date of this form."

Form 3 regulatory

"The options are fully vested and exercisable as of the date of this form."

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does CASI (CASIF) Global Chief Medical Officer report on this Form 3?

Alexander A. Zukiwski reports his derivative holdings in CASI options. He holds fully vested options to buy 116,333 Ordinary Shares at an exercise price of $1.93, all expiring on April 20, 2027, providing him equity-linked exposure.

How many CASI Pharmaceuticals (CASIF) shares can the reported options purchase?

The options allow purchase of 116,333 Ordinary Shares of CASI. This total comes from multiple option positions covering 30,000, 20,000, 3,000, 50,000, and 13,333 underlying shares, all reported as directly owned derivative holdings by the executive.

What is the exercise price of Alexander Zukiwski’s CASI (CASIF) options?

All reported options have an exercise price of $1.93 per Ordinary Share. This is the fixed price at which he can buy CASI stock before the options expire, regardless of the market price at the time of exercise.

When do Alexander Zukiwski’s CASI (CASIF) stock options expire?

Each reported option grant expires on April 20, 2027. After that date, any unexercised options lapse and can no longer be used to purchase Ordinary Shares, effectively ending the right to buy at the $1.93 exercise price.

Are the CASI (CASIF) options held by Alexander Zukiwski vested and exercisable?

Yes. A footnote states the options are fully vested and exercisable as of the form date. This means there are no remaining vesting conditions, and he can choose to exercise any or all of the options at his discretion before expiration.

Does this CASI (CASIF) Form 3 show any recent insider buying or selling?

No market transactions are indicated; it reports existing option holdings. The entries are classified as holdings with unknown transaction codes, and the summary data show no buys, sells, exercises, gifts, or tax-withholding dispositions in this particular filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Zukiwski Alexander A

(Last) (First) (Middle)

12003 TREGONING PLACE

(Street)

CLARKSBURG MARYLAND 20871

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
CASI Pharmaceuticals, Inc. [ CASIF ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Global Chief Medical Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)	(1)	04/20/2027	Ordinary Share	30,000	$1.93	D
Option (right to buy)	(1)	04/20/2027	Ordinary Share	20,000	$1.93	D
Option (right to buy)	(1)	04/20/2027	Ordinary Share	3,000	$1.93	D
Option (right to buy)	(1)	04/20/2027	Ordinary Share	50,000	$1.93	D
Option (right to buy)	(1)	04/20/2027	Ordinary Share	13,333	$1.93	D

Explanation of Responses:

1. The options are fully vested and exercisable as of the date of this form.

	/s/ Alexander Zukiwski	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)